Article

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale.

Tumor Biology and Angiogenesis Department, Genentech, Inc, One DNA Way, South San Francisco, CA 94080, USA.
Trends in Molecular Medicine (impact factor: 10.35). 02/2010; 16(3):122-32. DOI:10.1016/j.molmed.2010.01.004 pp.122-32
Source: PubMed

ABSTRACT Several ongoing clinical studies are designed to test the efficacy of antiangiogenic therapies in the adjuvant setting, where the goal is to increase the cure rate in patients who have just undergone surgical resection of all visible disease. Tumors depend on angiogenesis to support their growth and progression and blockade of this process has proven to be a valid strategy for treating multiple types of advanced metastatic cancer. However, results from the first of these clinical adjuvant studies were disappointing, stimulating extensive debate as to the potential of this approach. It will require additional clinical studies before we realize whether the effects of angiogenic blockade are durable, and if they are able to cure a subset of patients with early stage cancer.

0 0
 · 
0 Bookmarks
 · 
30 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

additional clinical studies
 
angiogenesis
 
antiangiogenic therapies
 
clinical adjuvant studies
 
cure rate
 
metastatic cancer
 
multiple types
 
ongoing clinical studies
 
patients
 
progression
 
stage cancer
 
stimulating extensive debate
 
surgical resection
 
visible disease